DE60210276D1 - Impfkomplex zur vorbeugung und behandlung von leishmaniasis - Google Patents

Impfkomplex zur vorbeugung und behandlung von leishmaniasis

Info

Publication number
DE60210276D1
DE60210276D1 DE60210276T DE60210276T DE60210276D1 DE 60210276 D1 DE60210276 D1 DE 60210276D1 DE 60210276 T DE60210276 T DE 60210276T DE 60210276 T DE60210276 T DE 60210276T DE 60210276 D1 DE60210276 D1 DE 60210276D1
Authority
DE
Germany
Prior art keywords
complex
impf
leishmaniasis
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60210276T
Other languages
English (en)
Other versions
DE60210276T2 (de
Inventor
Gerard Papierok
Serge Vicens
Jean-Loup Lemesre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Veto Test SARL
Original Assignee
Bio Veto Test SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Veto Test SARL filed Critical Bio Veto Test SARL
Application granted granted Critical
Publication of DE60210276D1 publication Critical patent/DE60210276D1/de
Publication of DE60210276T2 publication Critical patent/DE60210276T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60210276T 2001-06-11 2002-05-30 Impfkomplex zur vorbeugung und behandlung von leishmaniasis Expired - Fee Related DE60210276T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0107606A FR2825633B1 (fr) 2001-06-11 2001-06-11 Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
FR0107606 2001-06-11
PCT/FR2002/001823 WO2002100430A1 (fr) 2001-06-11 2002-05-30 Complexe vaccinal destine a la prevention et au traitement des leishmanioses

Publications (2)

Publication Number Publication Date
DE60210276D1 true DE60210276D1 (de) 2006-05-18
DE60210276T2 DE60210276T2 (de) 2006-11-30

Family

ID=8864170

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210276T Expired - Fee Related DE60210276T2 (de) 2001-06-11 2002-05-30 Impfkomplex zur vorbeugung und behandlung von leishmaniasis

Country Status (10)

Country Link
US (1) US20060073170A1 (de)
EP (1) EP1395282B1 (de)
AT (1) ATE321568T1 (de)
BR (1) BRPI0210317C1 (de)
CY (1) CY1105309T1 (de)
DE (1) DE60210276T2 (de)
ES (1) ES2260440T3 (de)
FR (1) FR2825633B1 (de)
PT (1) PT1395282E (de)
WO (1) WO2002100430A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2288379A4 (de) 2008-05-19 2012-08-08 Advaxis Doppeltes freisetzungssystem für heterologe antigene
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2566506B1 (de) * 2010-05-07 2016-07-06 Virbac Zusammensetzung eines impfstoffs zur verhinderung oder behandlung von leishmaniose
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
EP3332804A1 (de) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvanzien auf listerien-basis
EP2825195A4 (de) 2012-03-12 2015-10-07 Advaxis Inc Hemmung einer suppressorzellfunktion nach einer behandlung mit einem listerienimpfstoff

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206252A (en) * 1977-04-04 1980-06-03 Gordon Roy G Deposition method for coating glass and the like
US5599387A (en) * 1993-02-16 1997-02-04 Ppg Industries, Inc. Compounds and compositions for coating glass with silicon oxide
FR2705358B1 (fr) * 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.
AU5820199A (en) * 1998-09-17 2000-04-03 Libbey-Owens-Ford Co. Heat strengthened coated glass article and method for making same
US6342925B1 (en) * 1999-01-15 2002-01-29 Sharp Laboratories Of America, Inc. Automatic audio and video parameter adjustment
US7738550B2 (en) * 2000-03-13 2010-06-15 Sony Corporation Method and apparatus for generating compact transcoding hints metadata
BRPI0114262B1 (pt) * 2000-09-27 2018-09-25 Thomson Licensing Sa sistema para otimização automática dos modos de saída de áudio e vídeo para saída de um dispositivo multimídia
US6967588B2 (en) * 2002-03-25 2005-11-22 Sony Corporation System and method for controlling a home entertainment system

Also Published As

Publication number Publication date
WO2002100430A1 (fr) 2002-12-19
BR0210317A (pt) 2004-08-10
FR2825633B1 (fr) 2005-12-16
BRPI0210317B8 (pt) 2018-10-09
US20060073170A1 (en) 2006-04-06
PT1395282E (pt) 2006-07-31
ATE321568T1 (de) 2006-04-15
WO2002100430B1 (fr) 2003-02-13
DE60210276T2 (de) 2006-11-30
BRPI0210317B1 (pt) 2018-09-11
ES2260440T3 (es) 2006-11-01
EP1395282B1 (de) 2006-03-29
CY1105309T1 (el) 2010-03-03
FR2825633A1 (fr) 2002-12-13
EP1395282A1 (de) 2004-03-10
BRPI0210317C1 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
NO20034056D0 (no) Proliferative sykdommer
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60210276D1 (de) Impfkomplex zur vorbeugung und behandlung von leishmaniasis
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE60219687D1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
ATE508749T1 (de) Antidepressiva zur prophylaxe und therapie von zystischer fibrose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60231246D1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
DE50014268D1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60231994D1 (de) Mittel zur behandlung oder prävention allergischerg
DE60129552D1 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee